Major depressive disorder

G Grobler

1. Introduction

This treatment guideline draws on several international guidelines: (i) Practice Guidelines of the American Psychiatric Association (APA) for the Treatment of Patients with Major Depressive Disorder, Second Edition; (ii) Clinical Guidelines for the Treatment of Depressive Disorders by the Canadian Psychiatric Association and the Canadian Network for Mood and Anxiety Treatments (CANMAT); (iii) National Institute for Clinical Excellence (NICE) guidelines; (iv) Royal Australian and New Zealand College of Psychiatrists Clinical Practice Guidelines Team for Depression (RANZCAP); (v) Texas Medication Algorithm Project (TMAP) Guidelines; (vi) World Federation of Societies of Biological Psychiatry (WFSBP) Treatment Guideline for Unipolar Depressive Disorder; and (vii) British Association for Psychopharmacology Guidelines.

Major depressive disorder (MDD) is frequently associated with comorbid psychiatric and medical conditions and carries with it a high risk of morbidity and mortality. For many an initial episode of depression evolves into a recurrent and debilitating chronic illness with significant and pervasive impairments in psychosocial functioning. The recent Global Burden of Disease Study estimated that unipolar major depression is the fourth largest contributor to the global burden of disease (premature mortality and disability). By the year 2020, unipolar MDD is projected to be the second largest contributor to the global burden of disease, after heart disease.

1.1 Prevalence and risk factors

MDD has a median lifetime prevalence of 16.1% (range 4.4 - 18%). Twelve-month prevalence ranges from 5% to 10% in adults, with women at higher risk than men (ratio is approximately 2:1). In South Africa, the lifetime prevalence of MDD documented in the South African Stress and Health (SASH) survey, the first nationally representative epidemiological survey of common mental disorders in South Africa, was 9.8% across all age groups, with the highest prevalence (14.6%) in the Free State. The survey, conducted between 2003 and 2004 was a three-stage, area probability sample of 4 351 adults of all races and ethnic groups living in households and single-sex migrant labourer group quarters in South Africa. The 12-month prevalence rate of MDD during this period was 4.9%. The aforementioned SASH study found that females were 1.75 more likely to develop MDD than males.

The age of onset of MDD is difficult to assess because the first episode is frequently mild and untreated, and may be determined and retarded retrospectively many years after first onset. MDD can begin at any age, even in childhood and adolescence, but there are two peaks, in the twenties and forties. The mean age of onset of MDD has been estimated around the age of 30. Family and twin studies have indicated that MDD is a complex genetic disorder being 1.5 - 3 times more common among first-degree biological relatives of persons with this disorder than among the general population. Female gender, a previous episode of major depression and a positive first-degree family history of depression are the most consistently described risk factors.

1.2 Comorbidity and consequences

Anxiety disorders are highly comorbid, occurring in about 58% of patients with MDD. In addition, anxiety symptoms are highly prevalent in MDD, occurring in up to 80% of patients. Studies investigating the effects of depression on health-related quality of life have demonstrated detrimental effects that equal or exceed those of patients with chronic medical illnesses, such as ischaemic heart disease or diabetes mellitus. The most serious sequela of MDD is suicide. It has been estimated that about 50% of depressed patients make at least one suicide attempt during their lifetime. It is well established that patients with mood disorders suffer a higher risk of suicide relative to the general population. However, no risk factor or classification of diagnostic subtype has been shown to reliably predict suicide. In a recent meta-analysis, the lifetime prevalence of suicide was estimated, on the basis of the intensity of the treatment setting. The analysis showed that clinically depressed patients who had been hospitalised for suicidality had a lifetime risk of suicide of 8.6%. Patients with affective disorders, who had been hospitalised without specification of suicidality, had a lifetime suicide rate of 4.0%. The lifetime suicide prevalence for mixed inpatient/outpatient populations was 2.2%, and less than 0.5% for the non-affectively ill population. Depression also substantially increases the risk of death by cardiovascular disease.

In addition to the personal suffering of individuals and their families, depression imposes significant costs on society. These include both direct total healthcare costs and indirect costs (the latter have been estimated to be much higher than direct costs). Direct costs include mental health treatment costs and all other healthcare costs. Indirect costs include such varied factors as lost productivity associated with morbidity and mortality. As depression is often not properly diagnosed and/or undertreated, and as it can affect many individuals at a relatively early age, the impact on cost can be cumulative over time.

2. Diagnosis and clinical characteristics

MDD is characterised by single or recurrent major depressive episodes. The essential feature of a major depressive episode is a period of at least 2 weeks of depressed mood with abnormalities of neurovegetative functions (e.g. appetite, weight loss, sleep disturbances), psychomotor activity (e.g. loss of energy and interests, agitation or retardation), cognition (feelings of worthlessness, hopelessness or inappropriate guilt), as well as anxiety and suicidal ideation. Table 1 summarises the diagnostic criteria according to the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR) as well as the International Statistical Classification of Diseases and Related Health Problems, Tenth Revision (ICD-10).
Depressive symptoms and pathology lie on a spectrum in terms of duration, severity and comorbid pathology.

2.1 Course and prognosis
An untreated depressive episode typically lasts about 6 months or longer.[11,19,36] Modern pharmacotherapy alleviates suffering during acute episodes, and placebo-controlled trials show response and remission occurring more quickly in actively treated groups. A 27-year prospective study of 186 unipolar depressed patients meeting DSM-III criteria for major depression found shorter episodes and cycles with increasing episode number.[19] However, a 10-year prospective study of 258 subjects treated for unipolar MDD showed that the duration of recurrent mood episodes remained relatively uniform over time and averaged approximately 20 weeks.[19]

MDD is typically a recurrent disorder and 50 - 85% of the patients who have an episode will eventually have another episode.[16,41] There is also increasing evidence that some who experience a major depressive episode will have a lifelong course of illness characterised by recurrent major depressive episodes or the development of chronicity, e.g. recurrent MDD without full inter-episodic recovery, or a chronic major depressive episode, or 'double depression' (concurrent major depression and dysthymic disorder).[31,42-44] Between 9% and 24% of patients with the initial diagnosis of a major depressive episode will undergo a change in diagnosis over time, mostly to bipolar disorder.[19,39]

Although the prognosis for a depressive episode is good, with most patients returning to normal functioning once the episode is over, in 20 - 30% of cases depressive symptoms will persist.[40,43,45-47]

3. Assessment
A thorough diagnostic evaluation to determine both the presence of MDD and comorbid psychiatric or general medical conditions is key. This should include a review of the history of the illness including symptoms of current illness, past psychiatric and treatment history (with attention to current treatment and response to past treatment); general medical history; history of psychoactive substance abuse; personal developmental history and response to life transitions and major life events; social, occupational, and family history; mental status examination; physical examination; and laboratory investigations, as indicated.

Careful assessment of the patient's suicidal as well as homicidal risk is paramount. The APA guidelines[1] propose evaluation of the following:

- Presence of suicidal or homicidal ideation, intent, or plans
- Access to means for suicide and the lethality of those means
- Presence of psychotic symptoms, command hallucinations in particular, or severe anxiety
- Presence of alcohol or substance use disorder(s)
- History and seriousness of previous attempts
- Family history of, or recent exposure to, suicide.

Table 1. Criteria and classification of a depressive episode and major depressive disorder*

<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>A. Depressive episode</td>
<td>Major depressive disorder</td>
</tr>
<tr>
<td>Severe (F32.2): all 3 typical symptoms plus at least 4 other common symptoms; some severe symptoms</td>
<td>A. Single episode (296.2x)</td>
</tr>
<tr>
<td>Moderate (F32.1): at least 2 typical symptoms plus at least 3 common symptoms; some marked symptoms</td>
<td>B. Recurrent (296.3x)</td>
</tr>
<tr>
<td>Mild (F32.0): at least 2 typical symptoms plus at least 2 other common symptoms; no intense symptoms</td>
<td></td>
</tr>
<tr>
<td>B. Recurrent depressive disorder (F33): recurrent depressive episodes</td>
<td></td>
</tr>
</tbody>
</table>

Abridged criteria of depressive episode

- Minimum duration of episode: about 2 weeks
- Typical symptoms
  - Reduced energy, increased fatigability
  - Loss of interest and enjoyment
  - Depressed mood
- Other common symptoms
  - Diminished appetite
  - Disturbed sleep
  - Ideas or acts of self-harm or suicide
  - Agitation or retardation
  - Ideas of guilt and unworthiness
  - Reduced self-esteem and self confidence
  - Reduced concentration and attention

Abridged criteria major depressive episode

- A. Over the last 2 weeks, 5 of the following features should be present most of the day or nearly every day (must include 1 or 2):
  - Depressed mood
  - Loss of interest/pleasure in almost all activities
  - Significant weight loss/gain (>5% change in 1 month) or an increase or decrease in appetite nearly every day
  - Insomnia/hypersomnia
  - Psychomotor agitation or retardation (observable by others)
  - Fatigue or loss of energy
  - Feelings of worthlessness/excessive/inappropriate guilt (not merely self-reproach about being sick)
  - Diminished ability to think/concentrate, indecisiveness (either by subjective account or as observed by others)
  - Recurrent thoughts of death (not just fear of dying)/recurrent suicidal ideation/a suicide attempt/a specific plan for committing suicide
  - B. The symptoms cause clinically significant distress or impairment in social, occupational, or other important areas of functioning
  - C. Physical/organic factor or illness do not cause symptoms (e.g. drug abuse, medication, a general medical condition)
  - D. The symptoms are not better explained by bereavement (although this can be complicated by major depression)

Measurement-based diagnostic tools can aid in the assessment of depression severity, presence of co-occurring disorders, and suicide risk, but should always be accompanied by a clinical diagnostic assessment incorporating a differential diagnosis. Conditions that need to be excluded before making a definitive diagnosis of MDD include bipolar disorder, an adjustment disorder with depressed mood, mood disorder due to a general medical condition and a substance-induced mood disorder.

The Structured Clinical Interview for DSM-IV Axis I Disorders (SCID-I)\(^{[46]}\) and the Mini-International Neuropsychiatric Interview (MINI)\(^{[50]}\) are clinician-rated diagnostic instruments, while the 9-item Patient Health Questionnaire (PHQ-9)\(^{[51]}\) and the PRIME-MD\(^{[52]}\) are commonly used patient-rated tools. For monitoring of depressive symptoms on treatment, the Hamilton Depression Rating Scale (HAM-D)\(^{[53]}\) and the Montgomery-Åsberg Depression Rating Scale (MADRS)\(^{[54]}\) are gold-standard clinician-rated scales. Other measures include the Quick Inventory of Depressive Symptomatology (QIDS)\(^{[55]}\) which is available in both clinician-rated and patient-rated formats and the patient-rated Beck Depression Inventory (BDI).\(^{[56]}\)

Diagnostic assessment and evaluation of patient safety, as well as that of others, should be followed by an evaluation of functional impairment and determination of the treatment setting (inpatient or outpatient).

4. Treatment
4.1 Treatment goals
Definitions of response, remission, and recovery\(^{[2]}\) are summarised in Table 2.\(^{[57]}\) In depression, full remission is defined as the virtual elimination of symptoms which in most clinical trials refers to depression scores within the normal range. This is most consistently defined as a score of 7 or less on the 17-item Hamilton Depression Rating Scale (HRDS-17). The term ‘response’ generally indicates a 50% reduction in depression score. Recovery from depression is often equated with remission in the literature. It is also variably defined as remission for an extended period of time or the complete absence of symptoms which in most clinical trials refers to full remission.

Evidence for the benefits of treating remission in depression is clear: remitted patients are more likely to regain full functional recovery and to suffer fewer relapses and recurrences. Remission has become the accepted treatment goal in MDD, as seen in many recent clinical trials. In the current National Institutes for Mental Health Sequenced Treatment Alternatives to Relieve Depression (STAR*D) trial, for example, anything less than remission was viewed as treatment failure.\(^{[58,60]}\)

4.2 General aspects of treatment
Treatment consists of an acute phase (during which remission of all symptoms is induced); a continuation phase, during which remission is preserved; and a maintenance phase during which susceptible patients are protected against the recurrence of subsequent major depressive episodes.\(^{[51]}\)

4.3 Acute treatment
Initial management of MDD should entail: the establishment and maintenance of a therapeutic alliance; education of the patient and the family about the disorder with provision of information about treatment options; a review of the possible adverse effects of medications and potential drug-drug interactions; emphasis of the importance of taking medication as prescribed; and addressing the early signs of relapse.\(^{[53]}\) The appropriate treatment setting (inpatient or outpatient) should be selected and the treatment plan should be individualised to the patient’s needs.\(^{[62]}\)

Treatment decisions should also importantly take into account depression severity. A mild depressive episode, according to the DSM-IV-TR,\(^{[53]}\) is characterised by 5 or 6 symptoms or less and mild disability (social, occupational and other important areas of functioning), a moderate depressive episode by 6 or more symptoms and moderate disability, and a severe depressive episode by most of the symptoms (as per the DSM-IV-TR symptom list) and observable disability. According to the DSM-IV-TR, subthreshold depression comprises fewer than 5 symptoms.\(^{[57]}\) Guidelines differ in their opinion on the management of mild depression. The APA guidelines\(^{[1]}\) advise psychotherapy or antidepressant monotherapy based on patient preference. Similarly the CANMAT guidelines\(^{[2]}\) recommend either cognitive-behavioural therapy (CBT), cognitive therapy, interpersonal therapy (IPT), or antidepressants as a first-line treatment, while the BAP guidelines\(^{[60]}\) recommend CBT, behavioural therapy with activity scheduling, IPT or an antidepressant.

For moderate depression, all guidelines accept the use of an antidepressant or evidence-based psychotherapy as a first-line choice, with the exception of the NICE guideline which recommends antidepressants as the only first-line choice.\(^{[35]}\) In view of their superior tolerability and safety, the selective serotonin reuptake inhibitors (SSRIs), serotonin-norepinephrine reuptake inhibitors (SNRIs), or the norepinephrine-dopamine reuptake inhibitors (NDRIs), and mirtazapine are encouraged over the use of the tricyclic antidepressants (TCAs) and the monoamine oxidase inhibitors (MAOIs). However, the following considerations apply in deciding on the most appropriate medication: availability, safety, efficacy, tolerability, cost, and the need for long-term use.

### Table 2. Response, remission, and recovery definitions\(^{[57]}\)

<table>
<thead>
<tr>
<th>Outcome</th>
<th>Definition based on Hamilton Depression Rating Scale(^{[58]})</th>
</tr>
</thead>
<tbody>
<tr>
<td>Recovery</td>
<td>Remission and return of function</td>
</tr>
<tr>
<td>Remission</td>
<td>Response plus score of ≤7</td>
</tr>
<tr>
<td>Residual symptoms</td>
<td>Response plus score of ≥8</td>
</tr>
<tr>
<td>Response</td>
<td>≥50% reduction</td>
</tr>
<tr>
<td>Partial response</td>
<td>21 - 49% reduction</td>
</tr>
<tr>
<td>No response</td>
<td>≤20% reduction</td>
</tr>
</tbody>
</table>

and tolerability, patient preference and patient needs, and cost.\[60\] Newer antidepressant classes such a melatonin agonist may also be employed. Moderate depression may necessitate a combination of both an antidepressant and psychotherapy (either CBT or IPT); \(i\) electroconvulsive therapy (ECT) (6 to 10 treatments, maximum of 20, WFSBP guidelines recommend bilateral rather than unilateral ECT); \(ii\) a combination of an antidepressant with an antipsychotic agent for a major depressive episode with psychotic features.\[60\] In addition to using SSRIs as first-line agents, the WFSBP guidelines\[60\] also recommend TCAs and SNRIs as first-line options for severe depression. The RANZCAP guidelines\[60\] suggest a TCA or venlafaxine, an SNRI, as first-line treatment with lesser evidence for use of the SSRIs as first-line therapy. The RANZCAP guidelines also recommend the use of phenerzine or CBT for depression with atypical features. The BAP guidelines\[60\] do not consider psychotherapy alone as adequate for acute severe depression and recommend the use of an antidepressant as a first line. The aforementioned guidelines do not consider repetitive transcranial magnetic stimulation (RTMS), vagal nerve stimulation (VNS), hypericum extract (St John’s wort) or omega 3 supplementation as first-line treatments for severe depression, but consider light therapy as first-line treatment for seasonal affective disorder (SAD).

### 4.4 Pharmacological treatment

Dosage ranges for antidepressant medications are summarised in Table 3.\[1\] In order to improve tolerability, it may be necessary to initiate the patient on a subtherapeutic dose of an antidepressant (e.g. 10 mg fluoxetine) with gradual titration up to therapeutic dose levels. A medication trial should be of adequate dose and duration (i.e. 8 - 12 weeks). Cognisance should be taken of pharmacodynamic and pharmacokinetic properties of the selected antidepressant, and the expectation that efficacy may only be achieved following several weeks of treatment. The principle of ‘what gets you well, keeps you well’ should be kept in mind.

The patient should be monitored at regular intervals (fortnightly) to assess clinical status, response, side-effects, and safety, including worsening or emergence of suicidal ideation. Response can be assessed using a measurement-based tool such as the Clinical Global Impressions Scale (CGI). In addition to monitoring response of depressive symptoms, overall change in functioning, disability and subjective well-being should also be ascertained. If side-effects are intolerable, the patient should be switched to an alternative. Mirtazapine and bupropion, for example, may be useful in patients who experience SSRI-induced sexual dysfunction.

In general benzodiazepines (which do not have specific antidepressant effects) are not recommended as monotherapy and should be used judiciously as short-term adjunctive therapy (i.e. not longer than 4 weeks) to manage symptoms of anxiety, insomnia, and agitation\[60\] on an as-needed basis. Benzodiazepines should be avoided in patients with comorbid substance-use disorders.

### Table 3. Dosage ranges for antidepressant medications\[60\]

<table>
<thead>
<tr>
<th>Generic name</th>
<th>Starting dosage (mg/day)</th>
<th>Usual dosage (mg/day)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Tricyclics and tetracyclics</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Amitriptyline</td>
<td>25 - 50</td>
<td>100 - 300</td>
</tr>
<tr>
<td>Clomipramine</td>
<td>25</td>
<td>100 - 250</td>
</tr>
<tr>
<td>Doxepin</td>
<td>25 - 50</td>
<td>100 - 300</td>
</tr>
<tr>
<td>Imipramine</td>
<td>25 - 50</td>
<td>100 - 300</td>
</tr>
<tr>
<td>Trimipramine</td>
<td>25 - 50</td>
<td>100 - 300</td>
</tr>
<tr>
<td><strong>Secondary amine tricyclics (not available in SA)</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Desipramine</td>
<td>25 - 50</td>
<td>100 - 300</td>
</tr>
<tr>
<td>Nortriptyline</td>
<td>25</td>
<td>50 - 150</td>
</tr>
<tr>
<td>Protriptyline</td>
<td>10</td>
<td>15 - 60</td>
</tr>
<tr>
<td><strong>Tetracyclics</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Amoxapine</td>
<td>50</td>
<td>100 - 400</td>
</tr>
<tr>
<td>Maprotiline</td>
<td>50</td>
<td>100 - 225</td>
</tr>
<tr>
<td><strong>Selective serotonin reuptake inhibitors (SSRIs)</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Citalopram</td>
<td>20</td>
<td>20 - 40</td>
</tr>
<tr>
<td>Escitalopram</td>
<td>10</td>
<td>10 - 20</td>
</tr>
<tr>
<td>Fluoxetine</td>
<td>20</td>
<td>20 - 60</td>
</tr>
<tr>
<td>Fluvoxamine</td>
<td>50</td>
<td>50 - 300</td>
</tr>
<tr>
<td>Paroxetine</td>
<td>20</td>
<td>20 - 50</td>
</tr>
<tr>
<td>Sertraline</td>
<td>50</td>
<td>50 - 200</td>
</tr>
<tr>
<td><strong>Dopamine-norepinephrine reuptake inhibitors (NDRIs)</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Bupropion</td>
<td>150</td>
<td>150 - 300</td>
</tr>
<tr>
<td>Bupropion, sustained release</td>
<td>150</td>
<td>150 - 300</td>
</tr>
<tr>
<td>Bupropion, extended release</td>
<td>150</td>
<td>150 - 300</td>
</tr>
<tr>
<td><strong>Serotonin-norepinephrine reuptake inhibitors (SNRIs)</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Duloxetine</td>
<td>40</td>
<td>40 - 60</td>
</tr>
<tr>
<td>Venlafaxine</td>
<td>37.5</td>
<td>75 - 375</td>
</tr>
<tr>
<td>Venlafaxine, extended release</td>
<td>37.5</td>
<td>75 - 225</td>
</tr>
<tr>
<td><strong>Serotonin modulators</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Trazodone</td>
<td>50</td>
<td>75 - 400</td>
</tr>
<tr>
<td><strong>Monoamine oxidase inhibitors (MAOIs)</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mirtazapine</td>
<td>15</td>
<td>15 - 45</td>
</tr>
<tr>
<td><strong>Irreversible, nonselective</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Phenelzine</td>
<td>15</td>
<td>15 - 90</td>
</tr>
<tr>
<td>Tranylcypromine</td>
<td>10</td>
<td>30 - 60</td>
</tr>
<tr>
<td>Isocarboxazid</td>
<td>20</td>
<td>30 - 60</td>
</tr>
<tr>
<td><strong>Reversible MAO-I-A</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Moclobemide</td>
<td>300</td>
<td>300 - 600</td>
</tr>
<tr>
<td>Melatonergic agonist</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Agomelatine</td>
<td>25</td>
<td>25 - 50</td>
</tr>
</tbody>
</table>

4.5 Continuation and maintenance treatment

According to APA guidelines, the continuation phase is defined as the 16 - 20-week period that precedes sustained and complete remission from the acute phase. To prevent relapse, antidepressant medication should be continued at the same dose used during the acute phase. The aforementioned guidelines recommend that the frequency of visits be dictated to by the patient's condition and the specific treatment. Frequency can vary from once every 2 - 3 months to a few times per week.

On average, 50 - 85% of patients with a single episode of MDD will have at least one more episode. Therefore, following the continuation phase, maintenance phase treatment should be considered to prevent episodic recurrences. The following issues need to be borne in mind when considering maintenance treatment:

- The risk of recurrence (based on the number of previous episodes, presence of comorbid conditions, and residual symptoms between active episodes)
- The severity of episode(s) (based on the presence of suicidality, psychotic features, level of functional impairment)
- Side-effects associated with continuous treatment
- Patient preference.

The precise timing and methods of discontinuing psychotherapy and pharmacotherapy for depression have not been systematically evaluated. The decision to discontinue maintenance treatment should be based on the same factors guiding the decision to initiate maintenance treatment, including the probability of recurrence, the frequency and severity of past episodes, the persistence of depressive symptoms after recovery, the presence of comorbid disorders, and patient preference.

4.6 Non-pharmacological treatment

Non-pharmacological alternatives include psychotherapy (e.g. CBT, IPT) and newer alternatives that work on the basis of electric currents or magnetic impulses such as ECT, rTMS, VNS, and deep brain stimulation (DBS). Both CBT and IPT have been shown to be effective in acute depression (as monotherapy in mild depression and as augmentation in moderate and severe depression), and in preventing relapse and recurrence. ECT should be considered in patients with severe depression, in patients with depression with psychotic features, and in special circumstances or emergency situations. rTMS, VNS and DBS are not recommended as first- or second-line treatments in MDD.

4.7 Special populations

4.7.1 Subtypes

MDD may present with melancholia, with psychotic features, with atypical features, with catatonia, or as SAD. MDD with melancholic features is characterised by anhedonia, lack of reactivity to pleasurable stimuli and typical neurovegetative features such as worsening of mood in the morning, early morning waking, and marked weight loss. Although data are inconsistent, there is some evidence that venlafaxine and TCAs may be more effective than SSRIs for this depressive subtype. As mentioned previously, depression with psychotic features responds to the addition of an antipsychotic; however ECT is also an effective first-line option. Atypical depression is characterised by mood reactivity, significantly decreased energy or leaden feelings in the limbs (leaden paralysis), heightened sensitivity to interpersonal rejection, and a reversal of neurovegetative symptoms (increased sleep and appetite). SSRIs are considered first-line agents but monoamine oxidase inhibitors (MAOIs) are also effective (the latter have demonstrated superior efficacy to the TCAs). In these patients, it is important to consider medication that has a lower propensity for sedation or weight gain or a switch to mania. SAD, a subtype characterised by autumn/ winter depressive episodes and spring/summer hypomanic episodes, responds to both antidepressants (e.g. SSRIs) and light therapy. Both of the aforementioned treatments may be used as first-line, either separately or in combination. The extended release formulation of bupropion is US Food and Drug Administration (FDA)-approved for use in patients with this subtype (i.e. seasonal MDD). In patients with catatonia, ECT has been shown to be effective. Intravenous administration with a benzodiazepine (e.g. lorazepam, diazepam) may also induce rapid relief.

4.7.2 Comorbidity

Patients with coexisting dysthymic disorder usually have a better response to a combination of an antidepressant and psychotherapy than to either treatment alone. In patients with comorbid anxiety disorders, SSRIs or SNRIs are a good first choice. In addition, short-term augmentation with a benzodiazepine may be warranted and may also assist in enhancing compliance. In patients with comorbid panic disorder, it is prudent to start off with lower dose of an SSRI; in patients with comorbid obsessive-compulsive disorder (OCD) a serotonergic agent (SSRI or clomipramine) is advised; and in patients with comorbid social anxiety disorder, an SSRI or venlafaxine but not a TCA should be used. Psychotherapies such as CBT, behavioural therapy, and IPT may also be used to treat anxiety disorders and symptoms in this setting. Substance use disorders are often comorbid with MDD and in these patients an SSRI would be a good option although it may be necessary to detoxify these patients and then treat the substance use disorder first. For patients with comorbid borderline personality disorder, an SSRI or SNRI, should be considered. The behavioural impulsivity and dyscontrol can also be treated with a low-dose antipsychotic, lithium, or an antiepileptic medication.

In patients with comorbid medical disorders, the choice of antidepressant medication and the potential for multiple interactions with other medications need careful consideration; for example, in patients with cardiac disease TCAs should be avoided while in patients with stroke or epilepsy an SSRI is preferred. In HIV-infected patients, SSRIs are a preferred choice and are better tolerated than TCAs. For those patients on antiretroviral treatment, it is important to check for potential drug-drug interactions when choosing an antidepressant.

4.7.3 Suicidality

Debate about the risks of suicidal ideation and attempts following the initiation of antidepressant treatment continues. It is well known that as mood begins to improve on antidepressant treatment, so too do neurovegetative symptoms, energy and psychomotor activity. Patients may, therefore, act on pre-existing suicidal intent. Recent meta-analyses of data from clinical trials have shown a statistically
significant increase in suicidal thoughts or behaviours in depressed individuals aged 25 years or younger treated with antidepressant medications, compared with placebo, with a 1.5- to 2.5-fold increase in the relative risk.\textsuperscript{[79,80]} In contrast, no change in risk was detected for adults aged 25 to 64 years, while older adults (aged 65 years or older) on antidepressant treatment showed a decrease in the risk of suicidal thinking or behaviours. All antidepressants, in accordance with an FDA directive, carry a black-box warning that advises of the increased risk of suicidal thinking and behaviour pertaining to children, adolescents, and young adults.\textsuperscript{[81]}

4.7.4 Pregnancy and lactation

Both antidepressant use and untreated depression in pregnancy carry their own set of risks. Any decision to commence, continue, or discontinue an antidepressant needs to weigh up the risks and the benefits to mother and infant. Furthermore, it is important to bear in mind that relapse rates for women with a history of MDD are high during pregnancy, especially when antidepressants are discontinued.\textsuperscript{[82]}

The risk of teratogenicity with antidepressants following first-trimester exposure appears to be low overall. However, some rare birth defects have been observed to occur at higher rates with the use of specific SSRIs. For example first-trimester paroxetine exposure has been associated with cardiac malformations, a finding that resulted in changes in FDA labelling for paroxetine. Although most earlier reports\textsuperscript{[83]} suggested that SSRIs were not associated with a greater risk of congenital malformation, Chambers et al.\textsuperscript{[84]} have since shown that SSRIs can adversely affect fetal development. Antidepressant use in late pregnancy has been shown in some, but not all, studies to result in medical complications such as prematurity and transient neonatal withdrawal/adaptation syndrome.

ECT is both safe and effective during pregnancy and should be considered in pregnant women with moderate to severe depression who are unresponsive to, or unsuitable for, pharmacotherapy, for pregnant patients with psychotic features, and for pregnant patients who prefer this modality. MDD with postpartum onset is defined, in accordance with the same treatment principles delineated for other types of MDD.\textsuperscript{[85]}

While long-term evidence on the risks and benefits of antidepressant use during lactation are as yet not available, existing data suggest that antidepressants are compatible with breastfeeding. There have been case reports of adverse effects in breastfeeding infants exposed to maternal antidepressants but most studies have indicated low levels of exposure via breast milk with the SSRIs. The exception to this is fluoxetine, which appears to have a dose-related risk for detectable levels in infant sera.\textsuperscript{[86]}

5. Summary points

- First-line treatment for mild to moderate depression should consist of psychotherapy (CBT or IPT) either alone or in combination with an SSRI, an SNRI (e.g. venlafaxine), bupropion, mirtazapine or agomelatine.
- For severe depression, always consider an antidepressant as first-line (an SSRI, venlafaxine (SNRI), bupropion or mirtazapine) in combination with CBT or IPT, or alternatively consider ECT.
- Severe major depression with psychotic features warrants a combination of an antidepressant with an antipsychotic. ECT should also be considered. Consider a combination of either a tertiary amine tricyclic antidepressant with an antipsychotic agent (either a first- or second-generation antipsychotic); an SSRI in combination with an antipsychotic; or venlafaxine in combination with an antipsychotic.
- Choice of medication should be based on patient profile, side-effect profile, medication availability, nature of prior response to medication, comorbid psychiatric and medical conditions, patient preference, potential drug interactions and cost.
- If a patient presents without comorbidities and has had a previous satisfactory response to an SSRI, consider initiating treatment with a SSRI. If a patient presents with a comorbid anxiety or pain disorder, consider initiating treatment with an SSRI, SNRI or mirtazapine.
- Monitor patients initially at least fortnightly and continue medication treatment for 4 - 6 weeks.
- If remission is achieved, continuation treatment is warranted.
- With partial responders but not full remitters, increase the dose and continue for a further 4 - 6 weeks and reassess.
- With no response, choose to: (i) switch to another first-line medication from a different pharmaceutical class; (ii) augment with any one of the following: lithium, triiodothyronine (T3), an antipsychotic agent, an anticonvulsant/mood stabiliser; or (iii) combine an SSRI with a TCA, an SSRI with bupropion, an SSRI with mirtazapine, or venlafaxine with mirtazapine.

References


